OTS ASSOCIATION
The Association of Health Technology Assessment Specialists (HTA Association) is a non-profit organization that unites professionals to promote innovative approaches in healthcare. We work to make medical care in Russia better, more accessible, and more evidence-based.
The Association is headed by Professor Alexey Sergeevich Kolbin, Doctor of Medical Sciences, Honored Scientist of the Russian Federation, Head of the Department of Clinical Pharmacology and Evidence-Based Medicine at St. Petersburg State University. Professor Kolbin is a recognized expert in the field of clinical pharmacology, pharmacovigilance, and comprehensive health technology assessment.
Our key goals:
- Development and application of the concept of real-world data (RWD/RWE) for making informed decisions that affect the quality of health care.
- Support for comprehensive health technology assessment, pharmacovigilance and pharmacometrics to improve the efficiency of health care resource use.
- Promoting research and developing regulations governing the availability and quality of health care services.
- Improving the level of knowledge of specialists through educational programs, seminars and conferences.
We actively participate in the development of state and non-state programs aimed at improving the health care system, and also conduct an examination of lists of drugs and recommendations that affect the availability of treatment.
To achieve our goals, the Association:
- Trains specialists in the field of RWD/RWE, pharmacovigilance and pharmacometrics.
- Conducts educational events: lectures, seminars, forums, exhibitions and competitions.
- Engages in publishing activities, including the creation of books, magazines, video materials and electronic products.
- Provides consulting and methodological support to Association members.
The Association is located in St. Petersburg. We are open to new members interested in working together to improve the healthcare system and implement scientifically based approaches to the system of drug provision for patients with orphan diseases.
